| EMA number | EMEA/H/C/004889 |
| ATC code | A10 |
| Authorisation | 26 April 2019 |
| Withdrawn | 22 March 2022 |
| Revision | 3 |
Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ? 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.